Prophylactic Probiotics to Prevent Death or Sepsis in Preterm Infants in Colombia. A randomized, double-blind, multicenter trial.

Neonatal infections currently cause about 1.6 million deaths annually in developing countries. Preterm infants are especially vulnerable to infections because of their immature immune responses and their exposure to the hospital milieu, which promotes gastrointestinal colonization with Gram-negative...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2011
Institución:
Ministerio de Ciencia Tecnología e Innovación
Repositorio:
Repositorio Institucional de Minciencias
Idioma:
eng
OAI Identifier:
oai:repositorio.minciencias.gov.co:20.500.14143/40267
Acceso en línea:
https://repositorio.minciencias.gov.co/handle/20.500.14143/40267
Palabra clave:
Bajo peso al nacer
Mortalidad Neonatal
Neonato pretérmino
Probióticos
Sepsis neonatal
Rights
License
Derechos Reservados - Pontificia Universidad Javeriana, 2021
id E-ANAQUEL2_79ef9b1f62c42f4d36fcb47bfa92c45e
oai_identifier_str oai:repositorio.minciencias.gov.co:20.500.14143/40267
network_acronym_str E-ANAQUEL2
network_name_str Repositorio Institucional de Minciencias
repository_id_str
spelling Prophylactic Probiotics to Prevent Death or Sepsis in Preterm Infants in Colombia. A randomized, double-blind, multicenter trial.Bajo peso al nacerMortalidad NeonatalNeonato pretérminoProbióticosSepsis neonatalNeonatal infections currently cause about 1.6 million deaths annually in developing countries. Preterm infants are especially vulnerable to infections because of their immature immune responses and their exposure to the hospital milieu, which promotes gastrointestinal colonization with Gram-negative pathogens. Multiple studies have shown that the colonization of the bowel with probiotics (nonpathogenic anaerobic bacteria) competitively inhibit the attachment of Gram-negative pathogens decreasing their likelihood for bacterial translocation and the development of life threatening infections. This potential high-impact, low-cost intervention may significantly improve the survival and morbidity of preterm infants around the world. We propose to use the Colombian Neonatal Research Network (CNRN), a well-established and successful clinical research network, to test this hypothesis.A multi-center, double-blind, randomized, placebo-controlled trial, will be conducted in eight neonatal care units in three cities in Colombia. Patients with birth weight < 2000 grams, hemodynamically stable, who are admitted to hospital at 48 hours of age or less, and whose parents provide written consent, will be included in the trial. Neonates with evidence or suspicion of congenital intestinal obstruction or perforation, prenatal or postnatal diagnosis of gastroschisis, large omphalocele, or congenital diaphragmatic hernia, major congenital heart defects or anticipated transfer to a NICU not involved in the study are to be excluded. Enrolled neonates will be stratified according to participating institutions (eight strata) and birth weight (< 1500 grams and 1501 to 2000 grams) and randomly assigned to treatment with probiotics or placebo by using a computerized stratified balanced block randomization design. Assignment to treatment will be accomplished using sealed, sequentially numbered, opaque envelopes, color-coded for strata, available in each NICU pharmacy. For those randomized to the treatment arm, L reuteri DSM 17938 will be administered at a dose of 108 colony-forming units in 5 drops of a commercially available oil suspension once per day until discharge from the hospital (Biogaia AB, Stockholm, Sweden). For those randomized to the placebo arm, patients will receive an equal number of drops from an identical vial containing only the oil base, but without the probiotic. Vials of probiotic and placebo will only be identified by the pharmacist and according to randomization The preparations will be administered even if the patient has not begun a feeding protocol, given that there are no contraindications for feeding.Textos en Ingles y Español.Pontificia Universidad JaverianaBogotá: Pontificia Universidad Javeriana, 2021Pontificia Universidad Javeriana (PUJ) (Bogotá, Colombia)COL 0016784 - Unidad de Epidemiologia Clinica y BioestadìsticaLozano Leòn, Juan Manuel2021-09-21T15:02:56Z2021-09-21T15:02:56Z2011-10-20Informe de investigaciónhttp://purl.org/coar/resource_type/c_18wsTextinfo:eu-repo/semantics/workingPaperhttps://purl.org/redcol/resource_type/INFhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_8042267 páginas.application/pdfapplication/pdfhttps://repositorio.minciencias.gov.co/handle/20.500.14143/40267engBogotá (Cundinamarca, Colombia)2007-2011Derechos Reservados - Pontificia Universidad Javeriana, 2021https://creativecommons.org/licenses/by-nc-nd/4.0/Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)http://purl.org/coar/access_right/c_abf2oai:repositorio.minciencias.gov.co:20.500.14143/402672023-11-29T17:45:59Z
dc.title.none.fl_str_mv Prophylactic Probiotics to Prevent Death or Sepsis in Preterm Infants in Colombia. A randomized, double-blind, multicenter trial.
title Prophylactic Probiotics to Prevent Death or Sepsis in Preterm Infants in Colombia. A randomized, double-blind, multicenter trial.
spellingShingle Prophylactic Probiotics to Prevent Death or Sepsis in Preterm Infants in Colombia. A randomized, double-blind, multicenter trial.
Bajo peso al nacer
Mortalidad Neonatal
Neonato pretérmino
Probióticos
Sepsis neonatal
title_short Prophylactic Probiotics to Prevent Death or Sepsis in Preterm Infants in Colombia. A randomized, double-blind, multicenter trial.
title_full Prophylactic Probiotics to Prevent Death or Sepsis in Preterm Infants in Colombia. A randomized, double-blind, multicenter trial.
title_fullStr Prophylactic Probiotics to Prevent Death or Sepsis in Preterm Infants in Colombia. A randomized, double-blind, multicenter trial.
title_full_unstemmed Prophylactic Probiotics to Prevent Death or Sepsis in Preterm Infants in Colombia. A randomized, double-blind, multicenter trial.
title_sort Prophylactic Probiotics to Prevent Death or Sepsis in Preterm Infants in Colombia. A randomized, double-blind, multicenter trial.
dc.contributor.none.fl_str_mv Pontificia Universidad Javeriana (PUJ) (Bogotá, Colombia)
COL 0016784 - Unidad de Epidemiologia Clinica y Bioestadìstica
dc.subject.none.fl_str_mv Bajo peso al nacer
Mortalidad Neonatal
Neonato pretérmino
Probióticos
Sepsis neonatal
topic Bajo peso al nacer
Mortalidad Neonatal
Neonato pretérmino
Probióticos
Sepsis neonatal
description Neonatal infections currently cause about 1.6 million deaths annually in developing countries. Preterm infants are especially vulnerable to infections because of their immature immune responses and their exposure to the hospital milieu, which promotes gastrointestinal colonization with Gram-negative pathogens. Multiple studies have shown that the colonization of the bowel with probiotics (nonpathogenic anaerobic bacteria) competitively inhibit the attachment of Gram-negative pathogens decreasing their likelihood for bacterial translocation and the development of life threatening infections. This potential high-impact, low-cost intervention may significantly improve the survival and morbidity of preterm infants around the world. We propose to use the Colombian Neonatal Research Network (CNRN), a well-established and successful clinical research network, to test this hypothesis.
publishDate 2011
dc.date.none.fl_str_mv 2011-10-20
2021-09-21T15:02:56Z
2021-09-21T15:02:56Z
dc.type.none.fl_str_mv Informe de investigación
http://purl.org/coar/resource_type/c_18ws
Text
info:eu-repo/semantics/workingPaper
https://purl.org/redcol/resource_type/INF
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_8042
dc.identifier.none.fl_str_mv https://repositorio.minciencias.gov.co/handle/20.500.14143/40267
url https://repositorio.minciencias.gov.co/handle/20.500.14143/40267
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv Derechos Reservados - Pontificia Universidad Javeriana, 2021
https://creativecommons.org/licenses/by-nc-nd/4.0/
Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv Derechos Reservados - Pontificia Universidad Javeriana, 2021
https://creativecommons.org/licenses/by-nc-nd/4.0/
Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)
http://purl.org/coar/access_right/c_abf2
dc.format.none.fl_str_mv 267 páginas.
application/pdf
application/pdf
dc.coverage.none.fl_str_mv Bogotá (Cundinamarca, Colombia)
2007-2011
dc.publisher.none.fl_str_mv Pontificia Universidad Javeriana
Bogotá: Pontificia Universidad Javeriana, 2021
publisher.none.fl_str_mv Pontificia Universidad Javeriana
Bogotá: Pontificia Universidad Javeriana, 2021
institution Ministerio de Ciencia Tecnología e Innovación
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1860676510231298048